Algorae Pharmaceuticals Limited
LVCLF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | 0.43 | 0.32 | 0.55 |
| FCF Yield | -0.01% | -9.12% | -10.68% | -22.76% |
| EV / EBITDA | 0.00 | -8.61 | -9.52 | -3.26 |
| Quality | ||||
| ROIC | -103.19% | -68.93% | -55.49% | -48.77% |
| Gross Margin | 0.00% | 100.00% | 98.67% | 78.18% |
| Cash Conversion Ratio | 0.00 | 0.73 | 0.94 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 232.53% | -46.09% | 2.43% |
| Free Cash Flow Growth | 99.95% | 23.31% | 2.92% | -39.99% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 1.97 | 2.70 | 2.91 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 84.46 | -120,605.52 | -19,827.39 |